Trial Profile

A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 03 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Davunetide (Primary)
Indications Alzheimer's disease; Corticobasal degeneration; Dementia; Parkinsonian disorders; Progressive supranuclear palsy; Tauopathies
Focus Adverse reactions

Most Recent Events

23 Mar 2018 Status changed from active, no longer recruiting to completed.
05 Dec 2016 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017.
05 Dec 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com